AMW

About AMW

AMW GmbH is a German specialty pharmaceutical company founded in 2008 by Dr. Wilfried Fischer that focuses on developing and manufacturing biodegradable, controlled-release drug delivery systems. The company's core business revolves around parenteral sustained-release drug delivery systems, such as subcutaneous implants and transdermal patches, which release active pharmaceutical ingredients over extended periods. This approach aims to improve therapeutic outcomes, enhance patient adherence, and offer cost-effective therapies by reducing the frequency of administration and stress on the body.

AMW's primary market is in oncology, specifically for hormone-dependent tumors like prostate and breast cancer. The company has two key approved products: Goserelin and Leuprorelin implants. These implants are GnRH agonists that lower testosterone and estradiol levels, thereby treating hormone-sensitive cancers. Goserelin is available in one-month and three-month biodegradable implants, while the Leuprorelin implant provides a three-month release. The company has gained marketing authorizations for these products in Europe, Asia, Africa, and Latin America.

The company's business model encompasses the entire pharmaceutical value chain, from in-house research and development to manufacturing, intellectual property management, and global commercialization. AMW generates revenue through two main streams: out-licensing its approved products to global and local pharmaceutical partners for worldwide distribution and acting as a Contract Development and Manufacturing Organization (CDMO) for other pharmaceutical and medtech companies. In Germany, its subsidiary Endomedica GmbH markets the Leuprorelin implant under the brand name Leugon®. The company has shown significant growth, reporting a consolidated revenue of EUR 38.2 million in 2024, a 30% increase from the previous year.

Historically, the company has seen several strategic shifts and ownership changes. In 2018, it was acquired by a consortium led by Hybio Pharmaceutical and YF Capital to accelerate growth and international expansion. In March 2026, a new majority shareholding structure was announced with Ren Life Sciences and Juno Capital Partners, aiming to propel the company towards becoming a global leader in its field. AMW also embraces new technologies, having launched a research project in 2025 to optimize formulation development using artificial intelligence.